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Abstract
Background: The CpG island methylator phenotype (CIMP) is a distinct phenotype associated with microsatellite instability
(MSI) and BRAF mutation in colon cancer. Recent investigations have selected 5 promoters (CACNA1G, IGF2, NEUROG1,
RUNX3 and SOCS1) as surrogate markers for CIMP-high. However, no study has comprehensively evaluated an expanded set
of methylation markers (including these 5 markers) using a large number of tumors, or deciphered the complex clinical and
molecular associations with CIMP-high determined by the validated marker panel.
Metholodology/Principal Findings: DNA methylation at 16 CpG islands [the above 5 plus CDKN2A (p16), CHFR, CRABP1,
HIC1, IGFBP3, MGMT, MINT1, MINT31, MLH1, p14 (CDKN2A/ARF) and WRN] was quantified in 904 colorectal cancers by real-
time PCR (MethyLight). In unsupervised hierarchical clustering analysis, the 5 markers (CACNA1G, IGF2, NEUROG1, RUNX3 and
SOCS1), CDKN2A, CRABP1, MINT31, MLH1, p14 and WRN were generally clustered with each other and with MSI and BRAF
mutation. KRAS mutation was not clustered with any methylation marker, suggesting its association with a random
methylation pattern in CIMP-low tumors. Utilizing the validated CIMP marker panel (including the 5 markers), multivariate
logistic regression demonstrated that CIMP-high was independently associated with older age, proximal location, poor
differentiation, MSI-high, BRAF mutation, and inversely with LINE-1 hypomethylation and b-catenin (CTNNB1) activation.
Mucinous feature, signet ring cells, and p53-negativity were associated with CIMP-high in only univariate analysis. In
stratified analyses, the relations of CIMP-high with poor differentiation, KRAS mutation and LINE-1 hypomethylation
significantly differed according to MSI status.
Conclusions: Our study provides valuable data for standardization of the use of CIMP-high-specific methylation markers.
CIMP-high is independently associated with clinical and key molecular features in colorectal cancer. Our data also suggest
that KRAS mutation is related with a random CpG island methylation pattern which may lead to CIMP-low tumors.
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Introduction
Epigenetic aberrations are important mechanisms in human
carcinogenesis [1,2]. A number of tumor suppressor genes are
silenced by promoter CpG island methylation [3,4]. A subset of
colorectal cancers exhibit widespread promoter methylation,
which is referred to as the CpG island methylator phenotype
(CIMP) [4–7]. CIMP-high colorectal tumors have been associated
with older age, female sex, proximal location, mucinous and poor
differentiation, microsatellite instability (MSI), BRAF mutation,
high LINE-1 methylation level, wild-type TP53, stable chromo-
somes, and inactive WNT/b-catenin [8–23]. However, many of
these features are interrelated, and thus, it is essential to analyze a
large number of tumors by multivariate analysis to decipher the
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3698complex relations between CIMP-high and these clinical/tumoral
variables.
There is considerable heterogeneity of tumors with regard to
CpG island methylation, and not all CpG islands are methylated
in a similar manner in colorectal cancer [15]. Thus, choice of CpG
islands can substantially influence the features of CIMP. In fact,
different CIMP panels used in various studies have caused
considerable confusion [7]. Weisenberger et al. [15] have screened
195 CpG islands, and selected 5 loci (CACNA1G, IGF2, NEUROG1,
RUNX3 and SOCS1), which can serve as surrogate markers for
CIMP-high. We have further validated the use of 8 markers (the
above 5 plus CDKN2A (p16), CRABP1 and MLH1) as a CIMP-high
diagnostic panel [24]. However, no study has comprehensively
compared these CIMP-high-specific CpG islands and other CpG
islands using a large number of tumors.
In this study, we have assessed 16 CpG islands including the
new 5 CIMP markers as well as MINT (methylated in tumor)
markers and other CpG islands, utilizing hierarchical clustering
analysis on a large number of colorectal cancers. We have also
assessed the characteristics of CIMP-high tumors determined by a
validated marker panel, and interactions of various clinical and
tumoral factors by multivariate logistic regression analysis. This
study provides the rationale for standardization of CIMP-high-
specific methylation markers.
Methods
Study Group
We utilized the databases of two large prospective cohort studies;
the Nurses’ Health Study (NHS, N=121,700 women followed since
1976) [25,26], and the Health Professionals Follow-up Study (HPFS,
N=51,500 men followed since 1986) [26]. A subset of cohort
participants developed colorectal cancer during prospective follow-
up. Thus, these colorectal cancers represented a population-based,
relatively unbiased sample (compared to a single or few-hospital-
based sample). Previous studies on the cohorts have described
baseline characteristics of cohort participants and incident colorectal
cancer cases, and confirmed that our colorectal cancers were well
representative as a population-based sample [25,26]. Clinical
information was obtained through chart review by physicians. We
collected paraffin-embedded tissue blocks from hospitals where
participants had undergone resections of primary colorectal cancers.
Based on availability of adequate tissue specimens, a total of 904
colorectal cancer cases (406 from the men’s cohort and 498 from the
women’s cohort) were included. Clinical characteristics of the cases
are described in Table 1 (on the left, under the column heading ‘‘All
cases’’). Among our cohort studies, there was no significant difference
in demographic features between cases with tissue available and those
without available tissue [26]. Most tumors have previously been
characterized for statuses of MSI, CIMP, KRAS, BRAF, p53, b-
catenin, LINE-1 methylation and 14 of the 16 methylation markers
[19,21,24,27]. However, none of our previous studies have
comprehensively analyzed the 16 methylation markers in relation
to each other, independent associations of CIMP with various
clinical, pathological or tumoral molecular characteristics, or
interactions of various factors on the associations with CIMP-high
by comprehensive biostatistical methods. This study represents a
unique novel study in term of 1) a large sample size; 2) the validated
set of CIMP-specific methylation markers; 3) the number of other
molecular events analyzed, including 8 CpG islands other than the
CIMP-specific markers, MSI, KRAS, BRAF, p53, LINE-1 methyla-
tion and b-catenin; and 4) comprehensive statistical analyses
including unsupervised hierarchical clustering, smoothing splines to
assess nonlinearity, multivariate logistic regression, and stratified
logistic regression. Thus, this study obtained novel data from the
existing materials and database, analogous to novel studies using the
well-described cell lines or mouse models. Informed consent was
obtained from all study subjects. Tissue collection and analyses were
approved by the Harvard School of Public Health and Brigham and
Women’s Hospital Institutional Review Boards.
Pathologic Examination, DNA Extraction and Sequencing
of KRAS and BRAF
For all cases, pathologic features including tumor differentia-
tion, mucinous features and signet ring cells were examined by a
pathologist (S.O.). Poor differentiation was defined as the presence
of ,50% glandular area. Genomic DNA was extracted from
paraffin tissue, and PCR and Pyrosequencing targeted for KRAS
codons 12 and 13, and BRAF codon 600 were performed as
previously described [28,29].
Microsatellite Instability (MSI) Analysis
MSI status was determined by the MSI panel including
D2S123, D5S346, D17S250, BAT25, BAT26, BAT40, D18S55,
D18S56, D18S67 and D18S487 (i.e., 10-marker panel) as
previously described [24]. A ‘‘high degree of MSI’’ (MSI-high)
was defined as the presence of instability in $30% of the markers.
Real-time PCR (MethyLight) for Quantitative DNA
Methylation Analysis
Sodium bisulfite treatment on DNA and subsequent real-time
PCR (MethyLight [30]) was validated and performed as previously
described [31]. We quantified DNA methylation in 5 CIMP-
specific promoters (CACNA1G, IGF2, NEUROG1, RUNX3 and
SOCS1) and 11 other CpG islands [CDKN2A (p16), CHFR,
CRABP1, HIC1, IGFBP3, MGMT, MINT1, MINT31, MLH1,
p14 (CDKN2A/ARF), and WRN]. COL2A1 (the collagen 2A1 gene)
was used to normalize for the amount of template bisulfite-
converted DNA [31]. Primers and probes were previously
described [15,27], except for IGFBP3, p14 and WRN: IGFBP3-
F, 59-GTT TCG GGC GTG AGT ACG A-39 (Genbank
No. M35878, nucleotide Nos. 1692-1710); IGFBP3-R, GAA
TCG ACG CAAA CA CGA CTA C(nucleotide Nos. 1789-
1810) and IGFBP3-probe, 6FAM-TCG GTTG TT TAG GGC
GAA GTA CGG G-BHQ-1(nucleotide Nos. 1760-1784) (bisulfite-
converted nucleotides are highlighted by bold face and italics); P14
(CDKN2A/ARF)-F, 59- TTG GAG GCG GCG AGA ATA T-39
(Genbank No. L41934, nucleotide Nos. 238-256); P14-R, 59-
CCC CGT AAA CCG CGAA AT A-39 (nucleotide Nos. 332-
350); P14-probe, 6FAM-59- CGG TTCG TC GCG AGT GAG
GGT T-39 –BHQ-1 (nucleotide Nos. 299-320); WRN-F, 59-GTA
TCG TTC GCG GCG TTT AT-39 (Genbank No. AY442327,
nucleotide Nos. 1827-1846); WRN-R, 59-ACG AAA CCG ATA
TCC GAA ATC A -39 (nucleotide Nos. 1887-1908) and WRN-
probe, 6FAM-TTT TTTT TG CGG TCG TTG CGG G-BHQ-
(nucleotide Nos. 1855-1876). The PCR condition was initial
denaturation at 95uC for 10 min followed by 45 cycles of 95uC
for 15 sec and 60uC for 1 min. A standard curve was made for
each PCR plate by duplicated PCR amplifications for COL2A1 on
bisulfite-converted human genomic DNA at 4 different concen-
trations (in a 5-fold dilution series). The percentage of methylated
reference (PMR, i.e., degree of methylation) at a specific locus was
calculated by dividing the GENE:COL2A1 ratio of template
amounts in a sample by the GENE:COL2A1 ratio of template
amounts in SssI-treated human genomic DNA (presumably fully
methylated) and multiplying this value by 100. Methylation
positivity was set as PMR$4 as previously validated [31].
CIMP in Colorectal Cancer
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In order to accurately quantify relatively high LINE-1 methyl-
ation levels, we utilized Pyrosequencing as previously described
[21]. LINE-1 methylation level measured by Pyrosequencing has
beenshowntocorrelatewellwithoverall5-methylcytosinelevel(i.e.,
genome-wide DNA methylation level) in tumor cells [32,33].
Table 1. Clinical, pathologic and molecular characteristics of colon cancer cases according to CIMP status.
Clinical, pathological or molecular feature All cases CIMP-low/0 CIMP-high P value
Total N 904 771 133
Sex 0.003
Male 406 (45%) 362 (47%) 44 (33%)
Female 498 (55%) 409 (53%) 89 (67%)
Mean age6SD 66.368.4 65.768.5 69.466.9 ,0.0001
#
Tumor location‘ ,0.0001
Proximal 386 (45%) 270 (37%) 116 (89%)
Distal (excluding rectum) 282 (33%) 270 (37%) 12 (9.2%)
Rectum 199 (23%) 196 (27%) 3 (2.3%)
Tumor stage ,0.0001
I 203 (25%) 188 (28%) 15 (12%)
II 261 (33%) 193 (29%) 68 (54%)
III 229 (29%) 203 (30%) 26 (21%)
IV 106 (13%) 90 (13%) 16 (13%)
Tumor differentiation ,0.0001
Well/moderate 803 (91%) 710 (94%) 93 (70%)
Poor 83 (9.4%) 43 (5.7%) 40 (30%)
Mucinous component ,0.0001
0% 601 (66%) 545 (71%) 56 (42%)
1–49% 188 (21%) 152 (20%) 36 (27%)
$50% 115 (13%) 74 (9.6%) 41 (31%)
Signet ring cells ,0.0001
0% 844 (93%) 733 (95%) 111 (83%)
$1% 60 (6.6%) 38 (4.9%) 22 (17%)
MSI ,0.0001
Non-MSI-high 748 (85%) 707 (95%) 41 (31%)
MSI-high 127 (15%) 37 (5.0%) 90 (69%)
Mean LINE-1 methylation (%)6SD 61.469.6 60.769.6 65.168.3 ,0.0001
#
BRAF ,0.0001
Wild-type 748 (87%) 697 (95%) 51 (40%)
Mutated 113 (13%) 36 (4.9%) 77 (60%)
KRAS ,0.0001
Wild-type 557 (63%) 445 (59%) 112 (85.5%)
Mutated 326 (37%) 307 (41%) 19 (14.5%)
p53* ,0.0001
Negative 506 (57%) 403 (53%) 103 (77%)
Positive 386 (43%) 356 (47%) 30 (23%)
b-catenin* ,0.0001
Inactive (score 0–2) 499 (64%) 403 (60%) 96 (91%)
Active (score 3–5) 278 (36%) 269 (40%) 9 (8.6%)
(%) indicates the proportion of cases with a specific clinical feature within each MSI/CIMP subtype.
‘Proximal colon includes cecum to transverse colon, and distal colon includes splenic flexure to sigmoid colon.
*p53 and b-catenin status was determined by immunohistochemistry. Active b-catenin was defined as b-catenin score $3, where the b-catenin score was the sum of
nuclear (0, 1+ or 2+), cytoplasmic (0, 1+ or 2+) and membrane (0 or 1+ if expression is lost) scores as originally described by Jass et al.[35].
#t-test assuming unequal variances.
CIMP, CpG island methylator phenotype; LINE-1, long interspersed nucleotide element-1; MSI, microsatellite instability; SD, standard deviation.
doi:10.1371/journal.pone.0003698.t001
CIMP in Colorectal Cancer
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Tissue microarrays (TMAs) were constructed and immunohis-
tochemistry for p53 and b-catenin was performed as previously
described [19,34]. Appropriate positive and negative controls were
included in each run of immunohistochemistry. Cytoplasmic and
nuclear b-catenin expression was recorded separately as either no
expression (0), weak expression (1+), or moderate/strong expres-
sion (2+). The b-catenin activation score was calculated as the sum
of nuclear score (0–2), cytoplasmic score (0–2) and membrane
score (0 if membrane staining was positive, +1 if membrane
expression was lost), as originally described by Jass et al. [35]. All
immunohistochemically-stained slides were examined by one of
the investigator (b-catenin by K.N.; p53 by S.O.) unaware of other
data. Random samples of 402 and 118 tumors were re-examined
for b-catenin and p53, respectively, by a second observer (b-
catenin by S.O., p53 by K.N.) unaware of other data, and the
concordances between the two observers were 0.83 for b-catenin
(k=0.65, p,0.0001), and 0.87 for p53 (k=0.75, p,0.0001),
indicating substantial agreement.
Statistical Analysis
For cluster analysis of biomarkers including the 16 methylation
markers, MSI, KRAS and BRAF, we utilized average linkage
hierarchical clustering with a Euclidean distance metric as
implemented in MeV (http://www.tm4.org) [36]. The chi square
test was used to examine an association between CIMP and other
categorical variables of interest. The t-test assuming unequal
variances was performed to compare mean age and mean LINE-1
methylation level. The k coefficient was calculated to assess
agreement between each of the 16 markers (positive vs. negative)
and the 16-marker CIMP panel (CIMP-high positive vs. negative).
To examine the relations of a given variable and CIMP-high,
we utilized unconditional logistic regression models to calculate
odds ratios (ORs) for CIMP-high, according to the status of the
given variable, unadjusted and adjusted for age, sex, tumor
location, stage, differentiation, LINE-1 methylation level, and
status of MSI, KRAS, BRAF, p53 and b-catenin. To adjust for
potential confounding, age and LINE-1 methylation level were
used as continuous variables, and all of the other variables were
used as categorical variables.
For age and LINE-1, we assessed non-linearity by the likelihood
ratio test that compared a regression model including a quadratic
(or cubic) term with a model excluding it. The likelihood ratio test
showed that including the quadratic term did not significantly alter
model fit (p=0.86 for age, p=0.078 for LINE-1), and that
including the cubic term did not significantly alter model fit
(p=0.87 for age, p=0.084 for LINE-1). We also examined the
possibility of a non-linear relation between age (or LINE-1
methylation) and CIMP-high, non-parametrically with restricted
cubic splines [37].
We dichotomized tumor location (proximal vs. distal), tumor
differentiation (poor vs. well/moderate), signet ring cells (present vs.
absent), MSI (high vs. non-MSI-high), p53 (positive vs. negative),
KRAS (mutated vs. wild-type), BRAF (mutated vs. wild-type) and b-
catenin (active vs. inactive). There were 3 categories for mucinous
feature (0%, 1–49%, and $50%) in the initial main analysis
(Table 2). We dichotomized mucinous feature (present vs. absent)
in secondary stratified analyses and analyses of interactions, because
multivariate ORs for CIMP-high were similar across the 1–49%
mucinous and $50% mucinous categories (in reference to the non-
mucinous category). There were 4 categories for stage (I, II, III and
IV) in the initial main analysis (Table 2). We dichotomized tumor
stage (I vs. II–IV) in secondary stratified analyses and analyses of
interactions, because multivariate ORs for CIMP-high were similar
across stage II–IV (in reference to stage I).
When there was missing information on tumor stage (12%),
LINE-1 (3.9% missing), MSI (3.2% missing), p53 (1.3% missing),
KRAS (2.3% missing) or BRAF (4.7% missing), we assigned a
separate (‘‘missing’’) indicator variable and included those cases in
the multivariate analysis models. We confirmed that excluding
cases with a missing variable did not significantly alter results (data
not shown). There was no missing information in other variables.
An association of each variable with CIMP-high was also
assessed in strata of important clinical or molecular features,
including age (,65 year old vs. $65 year old), sex, tumor location
(proximal vs. distal), MSI status, and BRAF status. For stratified
analysis, each multivariate logistic regression model included a
variable of interest that was stratified by a given stratifying variable
(e.g., age) and adjusted for all of the remaining variables (SAS
codes available upon request).
An interaction was assessed by including the cross product term
of a given variable (e.g., MSI) and another variable of interest in a
regression model, and the likelihood ratio test compared a model
including the cross product term with that excluding it. In addition
to interactions of any given variable with MSI, location, age, sex
and BRAF, we examined all possible remaining two-way
interactions, and found no significant interactions (data not
shown).
All statistical analyses except for clustering analysis used SAS
version 9.1 (SAS Institute, Cary, NC). All p values were two-sided,
and statistical significance was defined as p#0.05. Nonetheless,
multiple hypotheses testing was considered when interpreting the
data, especially in examining multiple two-way interactions.
Results
Evaluation of 16 methylation markers
We obtained 904 colorectal cancer specimens and quantified
DNA methylation in the 16 loci [CACNA1G, IGF2, NEUROG1,
RUNX3, SOCS1, CDKN2A (p16), CRABP1, MLH1, CHFR, HIC1,
IGFBP3, MGMT, MINT1, MINT31, p14 (CDKN2A/ARF), and
WRN] by real-time PCR (MethyLight [30]) assays. The first 5 loci
(up to SOCS1) were selected as good predictors of CIMP (CpG
island methylator phenotype) by screening of 195 CpG islands
[15]. The use of the first 8 loci (up to MLH1) as a CIMP-high
diagnostic panel has been previously validated [24].
To evaluate 16 methylation markers in an unbiased fashion, we
conducted an unsupervised hierarchical clustering analysis of the
16 methylation markers and status of MSI (microsatellite
instability), and KRAS and BRAF oncogenes, using 860 tumors
with all of these results available (Figure 1). The 8 CIMP-high
markers (CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1,
NEUROG1, RUNX3 and SOCS1) were generally clustered together,
indicating good concordance of methylation patterns in these
markers and supporting these 8 markers as good CIMP-high
markers. In addition, p14, MINT31 and WRN were also clustered
with the 8 markers. The other 5 methylation markers (MGMT,
HIC1, CHFR, MINT1 and IGFBP3) were not clustered closely with
each other or the 8 markers. The BRAF and MSI variables, which
have been known to be associated with CIMP-high [15,18,24],
were also clustered together with these 8 markers, indicating tight
associations with CIMP-high. Notably, KRAS mutation was not
clustered with any of the methylation markers, suggesting its
association with a random methylation pattern (particularly in
CIMP-low tumors which have been associated with KRAS
mutation [29]; see also Supplemental Figure S1). We used
clustering analysis only for the examination of marker clustering,
CIMP in Colorectal Cancer
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markers was very stable with the large number of tumors (i.e.,
excluding a few tumors did not substantially influence results)
while tumor classification by clustering analysis based on the 16
markers was not stable.
To describe performance of each of the 16 markers in an
unbiased way, we calculated k coefficient (for agreement statistics),
sensitivity and specificity of each maker for CIMP-high diagnosis
determined by the 16 markers (Supplemental Table S1). The
cutoff for CIMP-high was set as $11/16 or $10/16 methylated
markers based on the distribution of KRAS and BRAF mutations
(Supplemental Figure), and on the previous findings that
CIMP-high is associated with BRAF mutation and CIMP-low is
associated with KRAS mutation [24,29]. Sensitivity and specificity
of each marker reflected overall concordance of a methylation
pattern with the remaining 15 markers. It was evident that
performance of the 8 CIMP-panel markers (CACNA1G, CDKN2A,
CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1) was
generally good. The k coefficient was greater than 0.5 for all of
these 8 markers. RUNX3 was the single best marker for CIMP-
high diagnosis. Among the other 8 markers (CHFR, HIC1,
IGFBP3, MGMT, MINT1, MINT31, p14 and WRN), only
MINT31 and p14 consistently showed the k coefficient greater
than 0.5, and good sensitivity/specificity. This was in agreement
with clustering analysis, which showed that MINT31 and p14
clustered with the 8 CIMP-panel markers.
We also compared the all-16-marker panel with the 8-marker
CIMP panel. Using the 8-maker panel, or the 16-maker panel,
CIMP-high was defined as $6/8 or $11/16 methylated markers,
respectively. Among the 904 cases, 879 cases (97.2%) showed
concordant diagnosis of CIMP status between the 16-marker panel
and the 8-marker panel (k=0.89, p,0.0001). When the 16-
marker CIMP panel was used, the associations of CIMP-high with
clinical and molecular features were very similar to the CIMP-high
associations by the 8-marker CIMP panel (data not shown). We
also confirmed a high degree of agreement (98.6% concordant;
k=0.94) between the 8-marker panel and the 5-marker panel
described by Weisenberger et al. [15]. Thus, in subsequent
analyses, we used the 8-marker CIMP panel which we had
extensively validated [24].
CIMP-high in colorectal cancer
We assessed clinical, pathologic and molecular features of
CIMP-high colorectal cancer (Table 1). By univariate analysis,
CIMP-high was associated with female sex, older age, proximal
location, poor differentiation, mucin, signet ring cells, MSI-high
and BRAF mutation, and inversely with stage I, KRAS mutation,
LINE-1 hypomethylation, positive p53, and active b-catenin (all
p,0.004).
Age was linearly associated with CIMP-high in logistic
regression analysis (p for trend ,0.0001). We did not show
significant non-linearity by the likelihood ratio test that compared
a model including a quadratic (or cubic) term with a model
excluding it (p.0.85). Likewise, LINE-1 hypomethylation was
inversely linearly associated with CIMP-high (p for trend
,0.0001), and there was no significant non-linearity by the
likelihood ratio test, using a quadratic (or cubic) term (p$0.078).
Non-parametric restricted cubic splines also supported a linear
Table 2. Associations with CIMP-high in colorectal cancer by univariate and multivariate analyses.
Clinical, pathological, or molecular
characteristics
Univariate OR
(95% CI) P value
OR adjusted for
major
confounder(s)
Major confounder(s)
(in the order of
strength of effect)
Multivariate OR
(95% CI) P value
Age (10-year increment) 1.78 (1.40–2.27) ,0.0001 2.53 (1.69–3.78) BRAF, MSI 3.16 (1.93–5.18) ,0.0001
Female (vs. male) 1.79 (1.22–2.64) 0.003 - - 1.96 (0.95–4.08) 0.071
Proximal (vs. distal)‘ 13.3 (7.64–23.3) ,0.0001 5.58 (2.80–11.1) MSI, BRAF 3.39 (1.57–7.34) 0.002
Tumor stage (vs. I) tumor location, MSI, BRAF
Stage II 4.42 (2.44–8.00) ,0.0001 2.53 (1.06–6.08) 1.83 (0.69–4.83) 0.23
Stage III 1.61 (0.83–3.12) 0.16 1.91 (0.72–5.12) 1.83 (0.63–5.28) 0.26
Stage IV 2.23 (1.06–4.71) 0.04 2.28 (0.78–6.65) 1.72 (0.53–5.62) 0.37
Poor differentiation 7.28 (4.50–11.8) ,0.0001 2.96 (1.42–6.19) MSI, BRAF 2.98 (1.15–7.69) 0.024
Mucinous feature (vs. 0%) MSI, BRAF
1–49% 2.31 (1.46–3.64) 0.0003 1.72 (0.89–3.29) 1.53 (0.71–3.32) 0.28
$50% 5.39 (3.37–8.63) ,0.0001 2.09 (1.03–4.24) 2.06 (0.81–5.22) 0.13
Signet ring cells, any 3.82 (2.18–6.71) ,0.0001 0.68 (0.32–1.41) mucin, differentiation 0.98 (0.30–3.17) 0.97
MSI-high 41.9 (25.5–68.9) ,0.0001 27.6 (16.2–47.1) tumor location 21.2 (9.79–45.8) ,0.0001
BRAF mutation 29.2 (18.0–47.6) ,0.0001 18.7 (11.0–31.7) tumor location 15.9 (6.60–38.4) ,0.0001
KRAS mutation 0.25 (0.15–0.41) ,0.0001 0.71 (0.36–1.40) BRAF, MSI 0.97 (0.44–2.10) 0.93
b-catenin activation* 0.14 (0.07–0.28) ,0.0001 0.21 (0.10–0.44) tumor location 0.21 (0.070–0.62) 0.005
LINE-1 hypomethylation (30% decline) 0.20 (0.10–0.39) ,0.0001 0.30 (0.13–0.69) MSI 0.27 (0.094–0.75) 0.012
p53 positivity 0.34 (0.22–0.52) ,0.0001 0.66 (0.39–1.13) MSI 0.73 (0.35–1.51) 0.39
Multivariate logistic regression model includes all of the above variables. Note that female, tumor stage, signet ring cells, mucinous feature, KRAS and p53 are not
significantly related with CIMP-high after adjusting for other variables.
*b-catenin activation is defined as b-catenin score $3. The b-catenin score is the sum of nuclear (0, 1+ or 2+), cytoplasmic (0, 1+ or 2+) and membrane (0 or 1+) scores as
originally described by Jass et al.[35].
‘Proximal colon includes cecum to transverse colon, and distal colon includes splenic flexure to rectum.
CI, confidence interval; CIMP, CpG island methylator phenotype; LINE-1, long interspersed nucleotide element-1; MSI, microsatellite instability; OR, odds ratio.
doi:10.1371/journal.pone.0003698.t002
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linear relation between LINE-1 hypomethylation and CIMP-high
(Figure 3).
In multivariate logistic regression analysis, CIMP-high was
significantly associated with older age, proximal location, poor
differentiation, MSI-high and BRAF mutation, and inversely with
active b-catenin and LINE-1 hypomethylation (Table 2). How-
ever, all of the other features (female, stage, mucin, signet ring
cells, KRAS and p53) were no longer significantly associated with
CIMP-high in multivariate analysis. We further examined for
potential confounders in the association of each variable with
CIMP-high. Except for sex, all of the other variables showed
substantial changes in odds ratio (OR) for the association with
CIMP-high after adjusting for MSI, BRAF and/or tumor location
(or other variables) (Table 2). These results indicated the existence
of complex relations between clinical and molecular features
(including CIMP) in colorectal cancer, which are summarized in
Figure 4.
Associations with CIMP-high in strata of MSI
Molecular classification by MSI status is increasingly important
in colorectal cancer [38–40]. Thus, we examined the relations of
clinical and tumoral variables with CIMP-high in MSI-high
tumors and non-MSI-high tumors (Table 3). Older age, proximal
location and BRAF mutation were significantly associated with
CIMP-high in both MSI-high and non-MSI-high tumors. In
contrast, the relations of CIMP-high with poor differentiation,
KRAS mutation and LINE-1 hypomethylation appeared to be
different according to MSI status (p for interaction ,0.005).
CIMP-high was associated with poor differentiation and inversely
with KRAS mutation in MSI-high tumors, but not in non-MSI-
high tumors. LINE-1 hypomethylation was inversely associated
with CIMP-high in non-MSI-high tumors, but not in MSI-high
tumors.
Associations with CIMP-high in strata of tumor location
There is accumulating evidence for a molecular difference
between proximal and distal colorectal cancers [38,41]. Therefore,
we examined the relations of clinical and tumoral variables with
CIMP-high in proximal tumors and distal tumors (Table 4). The
relations of CIMP-high with the variables did not appear to differ
according to tumor location (all p for interaction .0.23).
Associations with CIMP-high in other stratified analyses
We examined the relations of clinical and tumoral variables
with CIMP-high in strata of sex, age (,65 year old vs. $65 year
old) and BRAF status. Considering multiple hypotheses testing (12-
hypotheses testing each), the effect of the variables did not appear
to significantly differ according to age (all p for interaction .0.03)
and sex (all p for interaction .0.02). Notably, the effect of LINE-1
hypomethylation did appear to differ according to BRAF status (p
for interaction=0.001) (Table 5). A significant inverse association
of LINE-1 hypomethylation with CIMP-high was present in
BRAF-mutated tumors [adjusted OR=0.022; 95% confidence
interval (CI), 0.003–0.17], but not in BRAF-wild-type tumors
(adjusted OR=0.87; 95% CI, 0.25–3.06).
We also examined all of the remaining potential two-way
interactions by the available clinical and tumoral variables, and
Figure 1. Hierarchical clustering analysis of 16 methylation makers, MSI, KRAS and BRAF in colorectal cancers. Horizontal and vertical
axes represent markers and cases, respectively. The expanded view of clustering tree for the markers is shown on the right. The 8 markers in our
CIMP-high diagnostic panel (CACNA1G, IGF2, RUNX3, MLH1, SOCS1, CDKN2A (p16), CRABP1 and NEUROG1) are clustered closely, supporting that these
markers are good CIMP-high markers. Also note the close relationship between MSI, BRAF and the 8 CIMP-high markers. KRAS mutation is not
clustered with any of the methylation markers analyzed, suggesting that KRAS mutation (which is associated with CIMP-low [24,29]; see Supplemental
Figure) is probably associated with a random methylation pattern.
doi:10.1371/journal.pone.0003698.g001
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with CIMP-high (data not shown).
Discussion
In this study utilizing a large sample size, we evaluated 16
methylation makers in an unbiased fashion. The 16 methylation
markers included the 5 markers (CACNA1G, IGF2, NEUROG1,
RUNX3 and SOCS1) that were selected by screening of 195 CpG
islands [15] and further validated to be included in the CIMP-high
diagnostic panel (the above 5 plus CDKN2A, CRABP1 and MLH1)
[24]. By unsupervised hierarchical clustering analysis, the 5
methylation markers were clustered with each other as well as
with MSI (microsatellite instability) and BRAF mutation. Analysis
of k coefficient, sensitivity and specificity also demonstrated good
performance of the 5 methylation markers with generally
concordant methylation pattern. Utilizing the validated CIMP
panel, we have deciphered the complex relations of CIMP-high
Figure 2. Smoothing spline for the age/CIMP-high association. Loge(OR for CIMP-high) (y axis) according to age (x axis) is shown (with young
age as a referent). Broken lines indicate 95% confidence interval. Note the linear relation between age and CIMP-high. CIMP, CpG island methylator
phenotype; OR, odds ratio.
doi:10.1371/journal.pone.0003698.g002
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colorectal cancer. Our data provide a rationale for the of the
validated CIMP-specific methylation marker panel.
This study is the first extensive investigation to compare the 5
new CIMP-high markers [15] with MINT1, MINT31 and other
CpG islands, using a large sample size. Performance of the 5 new
markers (CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1),
CRABP1 and MLH1 was consistently superior to that of WRN,
MINT1, CHFR, IGFBP3, HIC1 and MGMT. MINT31, CDKN2A,
and p14 showed intermediate performance characteristics, and in
hierarchical clustering analysis, were generally clustered with the
new 5 CIMP markers, MSI and BRAF mutation. We have
provided valuable data for standardization of methylation markers
for the detection of CIMP-high in colorectal cancer.
Studying epigenetic and genetic aberrations is important in
cancer research [42–46]. We used quantitative PCR assays
(MethyLight [30]) to determine the degree of DNA methylation,
which is robust enough to reproducibly differentiate low-level
methylation from high-level methylation [31]. Our resource of a
large colorectal cancer sample obtained from two large prospective
Figure 3. Smoothing spline for the LINE-1/CIMP-high association. Loge(OR for CIMP-high) (y axis) according to LINE-1 methylation (x axis) is
shown (with high-level LINE-1 methylation as a referent). Broken lines indicate 95% confidence interval. Note the inverse linear relation between LINE-
1 hypomethylation and CIMP-high. CIMP, CpG island methylator phenotype; LINE-1, long interspersed nucleotide element-1; OR, odds ratio.
doi:10.1371/journal.pone.0003698.g003
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single-hospital-based sample) has provided a sufficient power to
evaluate the 16 methylation markers, and to simultaneously assess
independent relations of CIMP-high with multiple clinical and
tumoral molecular variables.
Interestingly, unsupervised clustering analysis using a large
number of tumors revealed that KRAS mutation was not clustered
with any of the 16 methylation markers. However, as shown in our
previous studies [24,29], KRAS mutation was more common in
CIMP-low tumors compared to CIMP-high and CIMP-0 tumors.
Although these findings appeared to be discrepant, we believe that
KRAS mutation is perhaps associated with a random pattern of
CpG island methylation, indicated by the non-clustering phenom-
enon in clustering analysis. In contrast, our clustering analysis has
clearly shown that BRAF mutation is clustered with CIMP-high
specific markers, indicating that BRAF mutation is perhaps
associated with a non-random pattern of CpG island methylation.
Previous studies identified various factors associated with
CIMP-high, including old age, female, proximal location, poor
differentiation, mucin, signet ring cells, MSI-high, BRAF mutation,
wild-type KRAS, inactive b-catenin, wild-type APC, high LINE-1
methylation level, and wild-type TP53 [9–19,21,47,48]. However,
many of these factors are interrelated. Thus, in order to properly
decipher the relations with CIMP-high, it is necessary to use a
large number of tumors, determine a number of molecular
features, and perform comprehensive biostatistical analysis. We
were able to utilize a large colorectal cancer sample that has been
examined for multiple molecular events, and appropriate biosta-
tistical methods. Figure 3 summarizes our current knowledge on
the associations of clinical, pathologic and molecular features
including CIMP in colorectal cancer. It is very important to keep
in mind these relations, when analyzing the association between
any of these factors and an outcome (e.g., molecular changes in
colorectal cancer, patient mortality, etc.). These factors may
confound the relationship of interest. Indeed, we have demon-
strated confounding effects of MSI, BRAF and tumor location in a
number of the associations in Table 2. In particular, signet ring
cells, KRAS and p53 were no longer associated with CIMP-high
after adjusting for the confounders.
We have shown that the relations of CIMP-high with tumor
differentiation, KRAS mutation and LINE-1 hypomethylation
appear to differ according to MSI status. MSI is a major
molecular classifier in colorectal cancer [38–40]. MSI-high tumors
have been shown to exhibit widespread mutations in nucleotide
repeat sequences such as those in TGFBR2 and BAX [49,50].
Thus, it is likely that overall genomic changes in MSI-high tumors
are dissimilar to those of non-MSI-high tumors. That may explain
Figure 4. Summary of associations of CIMP-high with clinical
and molecular features. The broken line indicates the relatively weak
association.
doi:10.1371/journal.pone.0003698.g004
Table 3. Associations with CIMP-high in MSI-high and non-MSI-high colorectal cancers.
Clinical, pathological, or
molecular characteristics
Pf o r
interaction
with MSI Among non-MSI-high tumors Among MSI-high tumors
Multivariate OR (95% CI) P value Multivariate OR (95% CI) P value
Age (10-year increment) 0.033 2.12 (1.23–3.65) 0.007 6.14 (2.49–15.1) ,0.0001
Female (vs. male) 0.46 1.41 (0.57–3.47) 0.45 2.03 (0.69–6.06) 0.20
Proximal (vs. distal)‘ 0.33 3.01 (1.22–7.40) 0.016 7.17 (1.74–29.5) 0.006
Tumor stage II–IV (vs. I) 0.064 0.97 (0.35–2.68) 0.95 4.92 (1.18–20.5) 0.029
Poor differentiation 0.002 0.84 (0.21–3.30) 0.80 25.6 (3.43–191) 0.002
Mucinous feature, any 0.29 2.02 (0.86–4.74) 0.11 0.95 (0.30–2.99) 0.93
Signet ring cells, any 0.22 1.65 (0.44–6.17) 0.46 0.42 (0.065–2.71) 0.36
BRAF mutation 0.21 11.7 (4.34–31.6) ,0.0001 49.8 (4.71–527) 0.001
KRAS mutation 0.004 2.24 (0.81–6.17) 0.12 0.17 (0.039–0.78) 0.022
p53 positivity 0.65 0.72 (0.31–1.70) 0.46 0.50 (0.12–2.00) 0.33
LINE-1 hypomethylation (30% decline) 0.002 0.095 (0.026–0.34) 0.0003 3.20 (0.47–22.0) 0.24
b-catenin activation* 0.18 0.32 (0.097–1.04) 0.058 0.063 (0.008–0.51) 0.009
Each multivariate logistic regression model assesses a variable of interest (stratified by MSI status in a given model), adjusting for all of the above remaining variables. An
interaction was assessed by the likelihood ratio test that compares a model including a cross product term (of the MSI variable and another variable of interest) with a
model excluding it.
*b-catenin activation is defined as b-catenin score $3, where the b-catenin score is the sum of nuclear (0, 1+ or 2+), cytoplasmic (0, 1+ or 2+) and membrane (0 or 1+)
scores as originally described by Jass et al.[35].
‘Proximal colon includes cecum to transverse colon, and distal colon includes splenic flexure to rectum.
CI, confidence interval; CIMP, CpG island methylator phenotype; LINE-1, long interspersed nucleotide element-1; MSI, microsatellite instability; OR, odds ratio.
doi:10.1371/journal.pone.0003698.t003
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differentially associated with CIMP-high according to MSI
status.
In summary, using the 16 methylation markers and a large
population-based sample, we have evaluated performance of each
of the 16 methylation markers in an unbiased fashion. Our current
Table 4. Associations with CIMP-high in proximal and distal colorectal cancers.
Clinical, pathological, or molecular
characteristics
Pf o r
interaction
with location Among proximal tumors‘ Among distal tumors‘
Multivariate OR (95% CI) P value Multivariate OR (95% CI) P value
Age (10-year increment) 0.32 2.62 (1.58–4.34) 0.0002 4.62 (1.61–13.2) 0.004
Female (vs. male) 0.71 1.93 (0.87–4.30) 0.11 1.21 (0.32–4.58) 0.78
Tumor stage II–IV (vs. I) 0.31 2.48 (0.79–7.79) 0.12 1.00 (0.24–4.15) 0.99
Poor differentiation 0.46 2.54 (0.91–7.10) 0.075 5.81 (0.89–37.8) 0.066
Mucinous feature, any 0.24 1.25 (0.58–2.72) 0.57 3.14 (0.79–12.5) 0.10
Signet ring cells, any 0.56 0.86 (0.25–2.94) 0.81 2.01 (0.18–22.6) 0.57
MSI-high 0.33 31.0 (13.2–73.2) ,0.0001 14.3 (3.28–62.5) 0.0004
BRAF mutation 0.56 13.7 (5.21–36.1) ,0.0001 22.8 (4.78–109) ,0.0001
KRAS mutation 0.39 1.20 (0.48–2.99) 0.70 0.57 (0.13–2.44) 0.44
p53 positivity 0.37 0.89 (0.39–2.06) 0.79 0.37 (0.083–1.63) 0.19
LINE-1 hypomethylation (30% decline) 0.26 0.19 (0.055–0.63) 0.007 0.65 (0.098–4.24) 0.65
b-catenin activation* -
# 0.35 (0.11–1.13) 0.078 0
# -
#
Each multivariate logistic regression model assesses a variable of interest (stratified by tumor location in a given model), adjusting for all of the above remaining
variables. An interaction was assessed by the likelihood ratio test that compares a model including a cross product term (of the location variable and another variable of
interest) with a model excluding it.
*b-catenin activation is defined as b-catenin score $3, where the b-catenin score is the sum of nuclear (0, 1+ or 2+), cytoplasmic (0, 1+ or 2+) and membrane (0 or 1+)
scores as originally described by Jass et al.[35].
‘Proximal colon includes cecum to transverse colon, and distal colon includes splenic flexure to rectum.
#Because there was no CIMP-high b-catenin-active tumors in distal colon, stable p for interaction and 95% CI for OR could not be estimated.
CI, confidence interval; CIMP, CpG island methylator phenotype; LINE-1, long interspersed nucleotide element-1; MSI, microsatellite instability; OR, odds ratio.
doi:10.1371/journal.pone.0003698.t004
Table 5. Associations with CIMP-high in BRAF-wild-type and BRAF-mutated colorectal cancers.
Clinical, pathological, or molecular
characteristics
Pf o r
interaction
with BRAF Among BRAF-wild-type tumors Among BRAF-mutated tumors
Multivariate OR (95% CI) P value Multivariate OR (95% CI) P value
Age (10-year increment) 0.13 3.60 (2.02–6.43) ,0.0001 1.80 (0.81–4.02) 0.15
Female (vs. male) 0.23 2.27 (1.01–5.09) 0.047 0.70 (0.14–3.51) 0.67
Proximal (vs. distal)‘ 0.56 3.87 (1.57–9.50) 0.003 2.33 (0.52–10.4) 0.27
Tumor stage II–IV (vs. I) 0.043 2.79 (0.92–8.45) 0.69 0.37 (0.070–1.94) 0.24
Poor differentiation 0.27 3.84 (1.27–11.6) 0.017 1.43 (0.32–6.49) 0.64
Mucinous feature, any 0.98 1.56 (0.69–3.56) 0.29 1.54 (0.45–5.30) 0.50
Signet ring cells, any 0.25 0.67 (0.15–3.09) 0.61 2.55 (0.40–16.3) 0.32
MSI-high 0.21 21.6 (9.56–48.6) ,0.0001 82.6 (8.48–804) 0.0001
KRAS mutation 0.37 1.02 (0.44–2.35) 0.96 0.18 (0.005–6.69) 0.35
p53 positivity 0.52 0.55 (0.21–1.40) 0.21 0.90 (0.26–3.06) 0.86
LINE-1 hypomethylation (30% decline) 0.001 0.87 (0.25–3.06) 0.83 0.022 (0.003–0.17) 0.0003
b-catenin activation* 0.44 0.20 (0.052–0.76) 0.018 0.49 (0.076–3.21) 0.46
Each multivariate logistic regression model assesses a variable of interest (stratified by BRAF status in a given model), adjusting for all of the above remaining variables.
An interaction was assessed by the likelihood ratio test that compares a model including a cross product term (of the BRAF variable and another variable of interest)
with a model excluding it.
*b-catenin activation is defined as b-catenin score $3, where the b-catenin score is the sum of nuclear (0, 1+ or 2+), cytoplasmic (0, 1+ or 2+) and membrane (0 or 1+)
scores as originally described by Jass et al.[35].
‘Proximal colon includes cecum to transverse colon, and distal colon includes splenic flexure to rectum.
CI, confidence interval; CIMP, CpG island methylator phenotype; LINE-1, long interspersed nucleotide element-1; MSI, microsatellite instability; OR, odds ratio.
doi:10.1371/journal.pone.0003698.t005
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CIMP-high-specific markers. Using the validated CIMP-specific
methylation marker panel, we have comprehensively analyzed the
clinical, pathologic and molecular features of CIMP-high
colorectal cancer by comprehensive biostatistical methods. We
have provided the rationale to use the validated CIMP-high-
specific methylation marker panel in clinical and research settings.
Further studies are necessary to elucidate fundamental molecular
defects that lead to CIMP-high colorectal cancer.
Supporting Information
Figure S1 Distribution of colorectal cancers according to the
number of methylated markers and KRAS/BRAF mutational
status. Note that KRAS mutation is associated with CIMP-low
(rather than CIMP-high and CIMP-negative), in agreement with
studies using more limited CIMP-specific methylation markers
[24,29].
Found at: doi:10.1371/journal.pone.0003698.s001 (0.12 MB TIF)
Table S1 Markers are listed in the order of the kappa coefficient.
* Sensitivity of each marker is defined as ‘‘[the number of CIMP-
high cases positive for a given marker] / [the number of all CIMP-
high cases]’’. ‘ Specificity of each marker is defined as ‘‘[the
number of non-CIMP-high cases negative for a given marker] /
[the number of all non-CIMP-high cases]’’.
Found at: doi:10.1371/journal.pone.0003698.s002 (0.15 MB
DOC)
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